{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T04:38:46Z","timestamp":1780634326853,"version":"3.54.1"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2000,4,1]],"date-time":"2000-04-01T00:00:00Z","timestamp":954547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"SmithKline Beecham Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Purpose. To demonstrate the efficacy of oral granisetron 1 mg twice daily for the prevention of late onset nausea and vomiting after moderately emetogenic chemotherapy that includes cyclophosphamide, carboplatin, or doxorubicin.<\/jats:p>\n               <jats:p>Methods. Prior to chemotherapy, patients were stratified by gender and randomized to receive oral granisetron (1 mg tablet twice daily) or prochlorperazine (10 mg sustained release capsule twice daily). Study agents were administered 1 h prior to and 12 h after chemotherapy. Antiemetics were administered for seven consecutive days. Efficacy variables were assessed 48 and 72 h after administration of chemotherapy, and included no emesis, no nausea, no moderate or severe nausea, and no antiemetic rescue. Safety analysis included all patients who received medication.<\/jats:p>\n               <jats:p>Results. A total of 230 patients were included in the intent-to-treat analysis; 119 patients received granisetron and 111 patients received prochlorperazine. Females, and all patients combined, who received granisetron had significantly higher no-emesis rates at 48 h (p = .010 and p = .016, respectively) than patients who received prochlorperazine. No-nausea rates at 48 h were numerically higher for all patients combined and females who received granisetron rather than prochlorperazine. Response rates for no nausea or mild nausea were also numerically higher in females treated with granisetron, compared to prochlorperazine, at 48 h. Significantly more patients (p &amp;lt; .001) and females (p &amp;lt; .001) in the granisetron group than in the prochlorperazine group did not require rescue antiemetics at 48 h. At 72 h, efficacy results were comparable for granisetron and prochlorperazine.<\/jats:p>\n               <jats:p>Conclusion. Oral granisetron is well tolerated and more effective than prochlorperazine in preventing nausea and vomiting for up to 48 h following treatment with moderately emetogenic chemotherapy.<\/jats:p>","DOI":"10.1634\/theoncologist.5-2-136","type":"journal-article","created":{"date-parts":[[2004,8,24]],"date-time":"2004-08-24T21:38:39Z","timestamp":1093383519000},"page":"136-143","source":"Crossref","is-referenced-by-count":13,"title":["Oral Granisetron for the Prevention of Acute Late Onset Nausea and Vomiting in Patients Treated with Moderately Emetogenic Chemotherapy"],"prefix":"10.1093","volume":"5","author":[{"given":"Carl J.","family":"Friedman","sequence":"first","affiliation":[{"name":"Clinical Research and Development, and Medical Affairs, North America, SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Howard A.","family":"Burris","sequence":"additional","affiliation":[{"name":"The Sarah Cannon Cancer Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Yocom","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, and Medical Affairs, North America, SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Blackburn","sequence":"additional","affiliation":[{"name":"Clinical Research and Development, and Medical Affairs, North America, SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gruben","sequence":"additional","affiliation":[{"name":"Biostatistics and Data Sciences, SmithKline Beecham Pharmaceuticals, Collegeville, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2000,4,1]]},"reference":[{"key":"2021122209515014000_R1","first-page":"6","article-title":"Preventing chemotherapy-induced nausea and vomiting: an update and a review of emesis","volume":"22","author":"Ettinger","year":"1995","journal-title":"Semin Oncol"},{"key":"2021122209515014000_R2","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000421-199604000-00023","article-title":"Frequency and clinical implications of delayed nausea and delayed emesis","volume":"19","author":"Morrow","year":"1996","journal-title":"Am J Clin Oncol"},{"key":"2021122209515014000_R3","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3109\/02841869009090058","article-title":"The natural course of emesis after carboplatin treatment","volume":"29","author":"Martin","year":"1990","journal-title":"Acta Oncol"},{"key":"2021122209515014000_R4","first-page":"1487","article-title":"The course of nausea and vomiting after high-dose cyclophosphamide","volume":"66","author":"Fetting","year":"1982","journal-title":"Cancer Treat Rep"},{"issue":"suppl 1","key":"2021122209515014000_R5","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000227637","article-title":"The severity and pattern of emesis following different cytotoxic agents","volume":"53","author":"Martin","year":"1996","journal-title":"Oncology"},{"key":"2021122209515014000_R6","first-page":"273","article-title":"Comparison of oral 5-HT3-receptor antagonists and low-dose oral metoclopramide plus i.m. dexamethasone for the prevention of delayed emesis in head and neck cancer patients receiving high-dose cisplatin","volume":"5","author":"Mantovani","year":"1998","journal-title":"Oncol Rep"},{"issue":"suppl 1","key":"2021122209515014000_R7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000227636","article-title":"Serotonin mechanisms in chemotherapy-induced emesis in cancer patients","volume":"53","author":"Cubeddu","year":"1996","journal-title":"Oncology"},{"key":"2021122209515014000_R8","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1200\/JCO.1998.16.4.1568","article-title":"Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly rmetogenic cisplatin-based chemotherapy","volume":"16","author":"Gralla","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209515014000_R9","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.1998.16.2.754","article-title":"Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study","volume":"16","author":"Perez","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122209515014000_R10","volume-title":"Kytril\u00ae (granisetron HCl) Tablets. Prescribing Information","year":"1998"},{"key":"2021122209515014000_R11","first-page":"85","article-title":"Efficacy and safety of oral granisetron versus oral prochlorperazine in preventing nausea and emesis in patients receiving moderately emetogenic chemotherapy","volume":"2","author":"Burris","year":"1996","journal-title":"Cancer J Sci Am"},{"key":"2021122209515014000_R12","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/j.1552-4604.1993.tb05608.x","article-title":"Participation of serotonin on early and delayed emesis induced by initial and subsequent cycles of cisplatinum-based chemotherapy: effects of antiemetics","volume":"33","author":"Cubeddu","year":"1993","journal-title":"J Clin Pharmacol"},{"key":"2021122209515014000_R13","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF00417481","article-title":"Control of emesis by intravenous granisetron in breast cancer patients treated with 5-FU, epirubicin and cyclophosphamide","volume":"2","author":"Tan","year":"1994","journal-title":"Support Care Cancer"},{"key":"2021122209515014000_R14","first-page":"46a","article-title":"High efficacy of oral granisetron in the total control of cyclophosphamide-induced prolonged emesis","volume":"17","author":"Guillem","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"2021122209515014000_R15","first-page":"937","article-title":"Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis","volume":"11","author":"Rosso","year":"1991","journal-title":"Anticancer Res"},{"key":"2021122209515014000_R16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1097\/00000421-199412000-00015","article-title":"Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses","volume":"17","author":"Campora","year":"1994","journal-title":"Am J Clin Oncol"},{"key":"2021122209515014000_R17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/BF00365581","article-title":"Delayed emesis following anticancer chemotherapy","volume":"2","author":"Kris","year":"1994","journal-title":"Support Care Cancer"},{"key":"2021122209515014000_R18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1080\/00325481.1993.11945731","article-title":"Chemotherapy-induced nausea and vomiting: easing patients' fear and discomfort with effective antiemetic regimens","volume":"94","author":"Bilgrami","year":"1993","journal-title":"Postgrad Med"},{"key":"2021122209515014000_R19","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/oxfordjournals.annonc.a059320","article-title":"Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis","volume":"6","author":"Italian Group for Antiemetic Research","year":"1995","journal-title":"Ann Oncol"},{"key":"2021122209515014000_R20","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2165\/00003495-199652050-00002","article-title":"Drug Treatment of chemotherapy-induced delayed emesis","volume":"52","author":"Tavorath","year":"1996","journal-title":"Drugs"},{"key":"2021122209515014000_R21","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1200\/JCO.1998.16.2.771","article-title":"Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center","volume":"16","author":"Nolte","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.5-2-136","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.5-2-136","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/2\/136\/41836892\/oncolo_5_2_136.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/5\/2\/136\/41836892\/oncolo_5_2_136.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T17:41:30Z","timestamp":1640194890000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/5\/2\/136\/6385836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,4,1]]},"references-count":21,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2000,4,1]]},"published-print":{"date-parts":[[2000,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.5-2-136","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2000,4,1]]},"published":{"date-parts":[[2000,4,1]]}}}